ClinicalTrials.gg
RecruitingNCT06113237Updated Nov 13, 2026

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

An observational study in Maternal Complications, Pregnancy Complication and Birth Outcomes, Adverse, sponsored by Jazz Pharmaceuticals. Recruiting at 3 sites in 3 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Jazz Pharmaceuticals · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 2, 2026First site in Italy1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 127 studies in Pregnancy Complications with a site in United States — 39 open to participants now, 47 under way, 1 of them phase 3. Pregnancy Complications · United States.

Planned enrollment
45th of 61
50 · median 477
Started
2025
with 16 others
Observational
61 of 127
20 open now
Primary completion
2033-08
later than 44 of 46 live
Registered
92nd of 127
by date

Among the 127 studies in Pregnancy Complications with a site in United States, this one is the 45th largest by planned enrollment of the 61 observational ones that give a count, is one of 17 that started in 2025, is one of 61 observational ones, reaches primary completion later than 44 of the 46 other live ones, and was the 92nd registered.

Pregnancy Complications

411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.

Browse Pregnancy Complications studies →

Open to participants now

39 of the 127 studies in Pregnancy Complications with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Pregnancy Complications with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.

03

Conditions studied

  • Maternal Complications
  • Pregnancy Complication
  • Birth Outcomes, Adverse
  • Pregnancy

Keywords

  • Epidiolex
  • Epidyolex
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants who were exposed to at least one dose of Epidiolex/Epidyolex during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with exposure to at least 1 dose of Epidiolex/Epidyolex during the 13 days prior to their LMP or at any time during pregnancy.
  2. Verbal or written to participate

Exclusion criteria

Exclusion criteria:

1) Patients exposed to a non-regulatory approved product containing Cannabidiol (CBD) during pregnancy who do not also have exposure to Epidiolex during the 13 days prior to their LMP or during the pregnancy.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective Pregnancy

    Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is no longer pregnant at the time of study enrollment.

    Drug: Epidiolex

  • Prospective Pregnancy

    Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is pregnant at the time of study enrollment.

    Drug: Epidiolex

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of MCM

    Rate of Major congenital malformation (MCM) identified in the developing neonate and infant through 12 months of age

    Time frame: Up to 12 months post birth

Secondary outcomes

  1. Rate of pregnancy outcomes

    Rate of the following pregnancy outcomes: 1. Spontaneous abortion 2. Elective or therapeutic abortion 3. Fetal death/stillbirth 4. Molar or ectopic pregnancy 5. Preterm delivery 6. Live birth

    Time frame: Up to 10 months gestation

  2. Rate of other events of interest in the developing neonate and infant

    Rate of the following other events of interest in the developing neonate and infant: 1. Hospitalizations for serious illness 2. Medications 3. Growth and development milestones 4. Neonatal or infant mortality 5. Inherited epilepsy syndrome

    Time frame: Up to 12 months post birth

  3. Rate of maternal complications during pregnancy

    Rate of the following maternal complications during pregnancy: 1. Premature rupture of membranes (PROM) 2. Pre-eclampsia 3. Severe pregnancy-induced hypertension 4. Proteinuria 5. Gestational diabetes 6. Intrauterine growth restriction (IUGR) 7. Measures of fetal growth deficiency (small for gestational age)

    Time frame: Up to 10 months gestation

07

Study locations

3 of 3 sites recruiting
  • United Biosource LLC
    Morgantown, West Virginia 26508, United States
    Recruiting
  • Vivantes Humboldt-Klinikum Klinik für Neurologie
    Berlin, 13509, Germany
    Recruiting
  • JZP047-102 Research Summary for UK IRAS application
    Bologna, 40138, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2033, 96 months after the start.

Of 121 observational studies under Pregnancy Complications, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 201. This study's planned 96 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 2, 2023
StartActual
Aug 5, 2025
Primary completionEst.
Aug 31, 2033
CompletionEst.
Aug 31, 2033
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Italy
Show site
  • JZP047-102 Research Summary for UK IRAS application · Bologna, Italy
Oct 2, 2026
Show all 2 updates
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 2, 2026
    1 site added — first site in Italy
    Show site
    • JZP047-102 Research Summary for UK IRAS application · Bologna, Italy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06113237
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Aug 5, 2025
Primary completion
Aug 31, 2033 (estimated)
Completion
Aug 31, 2033 (estimated)
Last update
Nov 13, 2026

Study contacts

Clinical Trial Disclosure & Transparency
Contact
ClinicalTrialDisclosure@JazzPharma.com
215-832-3750
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion